ONTRUZANT

Approval Id: 18bce5bcac70db11
Drug Approval Canada Name: ONTRUZANT
Product Name: ONTRUZANT
Status: Marketed
Status Date: 2022-07-20
Original Market Date: 2022-07-20
Din: 02524325
Drug Class: Human
Dosage Form: Powder For Solution
Route Of Administration: Intravenous
Schedule: Schedule D , Prescription
Ahfs: 10:00.00
Atc Original: L01FD01 TRASTUZUMAB
Atc Name: l 01 fd 01
Aig Number: 0154252001
Company Name: Samsung Bioepis Co., Ltd.
Company Address: 76, Songdogyoyuk-Ro, Yeonsu-Gu, Incheon, Incheon, Korea, Republic Of, 21987
Company Detail Path: /organization/samsung-bioepis-co-ltd

TRASTUZUMAB

440 MG / VIAL

Authorized

Agency

Health Canada

Country

🇨🇦

Approval Date

Jul 4, 2025

Approval ID

18bce5bcac70db11

Type

Standard